We are live on ! Find out more
CRMD icon

CorMedix
CRMD

14 hedge funds and large institutions have $5.08M invested in CorMedix in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

234% more capital invested

Capital invested by funds: $1.52M → $5.08M (+$3.56M)

180% more funds holding

Funds holding: 5 → 14 (+9)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.33% more ownership

Funds ownership: 1.52% → 1.85% (+0.33%)

Holders
14
Holders Change
+9
Holders Change %
+180%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$803K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$595K
3
SIM
Spark Investment Management
New York
+$137K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$116K
5
Morgan Stanley
Morgan Stanley
New York
+$81.9K

Top Sellers

Rank Fund Capital Flow
1
U
UBS
Switzerland
-$5.18K

CRMD Hedge Fund Activity: Q1 2014 in Review

14 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q1 2014, worth a combined $5.08M — up 234% from $1.52M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CRMD positions and 1 closed out — a net gain of 9 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Millennium Management, adding an estimated $803K. The largest seller was UBS, cutting an estimated $5.18K.

  • 14 institutional investors held CorMedix (CRMD) as of Q1 2014, up from 5 in Q4 2013.
  • Funds reported $5.08M of CorMedix stock for Q1 2014, up 234% quarter-over-quarter.
  • 10 funds opened new CorMedix positions in Q1 2014 and 1 closed out, a net change of +9 holders.
  • The largest CorMedix buyer in Q1 2014 was Millennium Management, an estimated $803K added.
  • The largest CorMedix seller in Q1 2014 was UBS, an estimated $5.18K sold.

Based on aggregated 13F filings for Q1 2014.